Treatment of elderly patients with metastatic renal cell carcinoma

Elisa Zanardi, Paolo Grassi, Alessia Cavo, Elena Verzoni, Claudia Maggi, Filippo De Braud, Francesco Boccardo, Giuseppe Procopio

Research output: Contribution to journalArticle

Abstract

The risk of developing renal cell carcinoma (RCC) increases with age, and given the constant gain in life expectancy of the general population, both localized RCC and metastatic RCC (mRCC) are more frequently observed in the elderly population. The elderly are a heterogeneous group of patients often characterized by the presence of comorbidities, different compliance to treatment and polypharmacy. Here we review the available data with the aim to analyze the safety and efficacy of new targeted therapies (TTs) in elderly mRCC patients. TTs seem to be effective in both older and younger patients, but elderly patients appear to show reduced tolerance to treatments compared to younger patients. Prospective trials are needed to better understand how to manage mRCC in elderly patients.

Original languageEnglish
Pages (from-to)323-334
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume16
Issue number3
DOIs
Publication statusPublished - Mar 3 2016

Fingerprint

Renal Cell Carcinoma
Therapeutics
Polypharmacy
Life Expectancy
Population
Comorbidity
Safety

Keywords

  • elderly
  • geriatric oncology
  • mRCC
  • Renal cell carcinoma
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Treatment of elderly patients with metastatic renal cell carcinoma. / Zanardi, Elisa; Grassi, Paolo; Cavo, Alessia; Verzoni, Elena; Maggi, Claudia; De Braud, Filippo; Boccardo, Francesco; Procopio, Giuseppe.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 3, 03.03.2016, p. 323-334.

Research output: Contribution to journalArticle

Zanardi, Elisa ; Grassi, Paolo ; Cavo, Alessia ; Verzoni, Elena ; Maggi, Claudia ; De Braud, Filippo ; Boccardo, Francesco ; Procopio, Giuseppe. / Treatment of elderly patients with metastatic renal cell carcinoma. In: Expert Review of Anticancer Therapy. 2016 ; Vol. 16, No. 3. pp. 323-334.
@article{7b3d0d85548e472a98ee6a8576cd9066,
title = "Treatment of elderly patients with metastatic renal cell carcinoma",
abstract = "The risk of developing renal cell carcinoma (RCC) increases with age, and given the constant gain in life expectancy of the general population, both localized RCC and metastatic RCC (mRCC) are more frequently observed in the elderly population. The elderly are a heterogeneous group of patients often characterized by the presence of comorbidities, different compliance to treatment and polypharmacy. Here we review the available data with the aim to analyze the safety and efficacy of new targeted therapies (TTs) in elderly mRCC patients. TTs seem to be effective in both older and younger patients, but elderly patients appear to show reduced tolerance to treatments compared to younger patients. Prospective trials are needed to better understand how to manage mRCC in elderly patients.",
keywords = "elderly, geriatric oncology, mRCC, Renal cell carcinoma, targeted therapy",
author = "Elisa Zanardi and Paolo Grassi and Alessia Cavo and Elena Verzoni and Claudia Maggi and {De Braud}, Filippo and Francesco Boccardo and Giuseppe Procopio",
year = "2016",
month = "3",
day = "3",
doi = "10.1586/14737140.2016.1131613",
language = "English",
volume = "16",
pages = "323--334",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Treatment of elderly patients with metastatic renal cell carcinoma

AU - Zanardi, Elisa

AU - Grassi, Paolo

AU - Cavo, Alessia

AU - Verzoni, Elena

AU - Maggi, Claudia

AU - De Braud, Filippo

AU - Boccardo, Francesco

AU - Procopio, Giuseppe

PY - 2016/3/3

Y1 - 2016/3/3

N2 - The risk of developing renal cell carcinoma (RCC) increases with age, and given the constant gain in life expectancy of the general population, both localized RCC and metastatic RCC (mRCC) are more frequently observed in the elderly population. The elderly are a heterogeneous group of patients often characterized by the presence of comorbidities, different compliance to treatment and polypharmacy. Here we review the available data with the aim to analyze the safety and efficacy of new targeted therapies (TTs) in elderly mRCC patients. TTs seem to be effective in both older and younger patients, but elderly patients appear to show reduced tolerance to treatments compared to younger patients. Prospective trials are needed to better understand how to manage mRCC in elderly patients.

AB - The risk of developing renal cell carcinoma (RCC) increases with age, and given the constant gain in life expectancy of the general population, both localized RCC and metastatic RCC (mRCC) are more frequently observed in the elderly population. The elderly are a heterogeneous group of patients often characterized by the presence of comorbidities, different compliance to treatment and polypharmacy. Here we review the available data with the aim to analyze the safety and efficacy of new targeted therapies (TTs) in elderly mRCC patients. TTs seem to be effective in both older and younger patients, but elderly patients appear to show reduced tolerance to treatments compared to younger patients. Prospective trials are needed to better understand how to manage mRCC in elderly patients.

KW - elderly

KW - geriatric oncology

KW - mRCC

KW - Renal cell carcinoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84959544701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959544701&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1131613

DO - 10.1586/14737140.2016.1131613

M3 - Article

AN - SCOPUS:84959544701

VL - 16

SP - 323

EP - 334

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 3

ER -